InspireMD Inc. (NSPR) News
Filter NSPR News Items
NSPR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NSPR News From Around the Web
Below are the latest news stories about INSPIREMD INC that investors may wish to consider to help them evaluate NSPR as an investment opportunity.
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025MIAMI, Dec. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Mr. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition. Marvin Slosman, Chief Executive Officer of InspireMD, commented, “Craig |
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)Study represents a significant step forward in Company’s mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutionsMIAMI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergo |
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of DirectorsMIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, sta |
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)InspireMD ( NASDAQ:NSPR ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.81m (up 16% from 3Q 2023). Net... |
InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...InspireMD Inc (NSPR) reports a 16.3% revenue increase while navigating higher expenses and gearing up for a pivotal U.S. market entry. |
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update– Submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval of the CGuard Prime carotid stent system in the U.S. – – Announced approval of an IDE application to initiate the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures – – Established its Headquarters in Miami, Florida, to optimally support the anticipated U.S. commercial launch of CGuard Prime in H1 2025, if approved – Achieved another record high revenue and un |
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee |
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2024 financial results on Tuesday, November 12th, 2024, before the financial markets open. Management will host a conference call and webcast with the investment comm |
One InspireMD Insider Raised Stake By 13% In Previous YearInsiders were net buyers of InspireMD, Inc.'s ( NASDAQ:NSPR ) stock during the past year. That is, insiders bought more... |
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent SystemMIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved. Marvin Slosman, Chief Executive Officer of InspireMD, stated, |